Nevro Corp
NYSE:NVRO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (1.2), the stock would be worth $7.13 (22% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1 | $5.84 |
0%
|
| 3-Year Average | 1.2 | $7.13 |
+22%
|
| 5-Year Average | 3 | $18.45 |
+216%
|
| Industry Average | 3.1 | $19.07 |
+226%
|
| Country Average | 2.5 | $15.35 |
+163%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Nevro Corp
NYSE:NVRO
|
220.9m USD | 1 | -1.9 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.7B USD | 9.3 | 58 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
163B USD | 3.1 | 26 | |
| US |
|
Stryker Corp
NYSE:SYK
|
122.9B USD | 5.5 | 37.9 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
105.1B USD | 2.1 | 22.8 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
86.7B USD | 3.6 | 24.3 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.8B USD | 4.6 | 43.6 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.8B EUR | 2.2 | 18.8 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.3B USD | 28.2 | 42.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.6B USD | 1.7 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.6B USD | 5 | 21.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Nevro Corp
Glance View
Nevro Corp. engages in the provision of medical devices. The company is headquartered in Redwood City, California and currently employs 945 full-time employees. The company went IPO on 2014-11-06. The firm has developed and commercialized the Senza spinal cord stimulation (SCS) system. SCS is a neuromodulation platform for the treatment of chronic pain, with the Senza Omnia platform, which is in addition to the Senza family of products. The Company’s solution for chronic pain includes 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain based on what it believes to be the best clinical evidence available. The advantages of its 10 kHz Therapy over traditional SCS include demonstrated superior efficacy data for both leg and back pain, paresthesia free pain relief for patients, anatomical lead placement for physicians, and ability to treat a broader group of chronic pain patients.
